| abstract |
The disclosed 5-(hydroxymethyl)oxazolidin-2-one derivatives are 3-substituted by an indazol, benzisoxazol or benzisothiazol ring and have the general formula (I), in which X stands for an oxygen atom, a sulphur atom or a NR group, R being a hydrogen atom or a linear or branched C1-C4 alkyl chain; R1 stands for a hydrogen atom or a methyl group; and R2 stands for either (i) a R3O group in which R3 stands for a hydrogen atom or a benzyl group optionally substituted by a halogen atom or by a nitro or methylene dioxy group, or for a methoxyethyl, butyl, 4,4,4-trifluorobutyl, 4,4,4-trifluoro-3-hydroxybutyl or 4,4,4-trifluorobut-2-enyl group; or for (ii) a -CH=CH-R or -CH2-CH2-R4 group in which R4 stands for a hydrogen atom or a phenyl, 3,3,3-trifluoropropyl or 3,3,3-trifluoro-2-hydroxypropyl group. Also disclosed are their process of preparation and their therapeutical applications. |